Abstract:Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive and highly heterogeneous lymphoma, and for high-risk group who has an International Prognostic Index (IPI) score of 3-5 it is more difficult to treat (Teras LR,2016; Ziepert M,2010). Under the standard R-CHOP-like immunochemotherapy, the 3-year overall survival (OS) rate of patients with IPI score of 0-1, 2, 3, 4-5 were 91%, 81%, 65% and 59%, respectively (Ziepert M,2010). The efficacy for high-risk population (IPI 3-5) was limited even after intensive chemotherapy, with an ORR of 74.5% and CR of 47.3% under R-CODOX-M/R-IVAC (McMillan AK,2020). Nonetheless, adding new agents to R-CHOP shows better efficacy in patients with IPI 3-5(Tilly H,2022; Nowakowski GS,2021). GCB subtype has better prognosis, but 20% of patients still relapsed after R-CHOP therapy (Nowakowski GS,2015), and no more benefit was achieved by modifying regimen with new agents like polatuzumab-R-CHP (Tilly H,2022), adding on lenalidomide (Nowakowski GS,2015) or ibrutinib (Wilson WH,2021). Selinexor is the only approved oral selective nuclear export inhibitor which demonstrated a 34% ORR in GCB subgroup as a monotherapy in relapsed/refractory DLBCL (Kalakonda N,2020). Selinexor combined with R-CHOP showed a CR rate of 58.8% and ORR of 94.1% in 17 high risk GCB DLBCL patients in a real-world setting (Zhiming Li,2023). This phase 2 study (NCT05422066) further explored the benefit and safety of Selinexor plus R-CHOP in the treatment of newly diagnosed (ND) GCB DLBCL patients with IPI 3-5. Methods This is a multicenter, open label, single arm phase 2 study enrolled 18~75 years old ND GCB DLBCL patients with IPI 3-5. Patients were administered selinexor 60mg QW in combination with standard R-CHOP therapy for 6 cycles (Rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2, doxorubicin 50 mg/m 2 IV, vincristine 0.5 mg/kg on day 1, prednisone 100 mg PO on days 1-5 in a 21-day cycle). The primary endpoint is complete remission (CR) rate. Secondary endpoints include objective response Rate (ORR), progression free survival (PFS), disease free survival (DFS), overall survival (OS), safety and tolerability. Results The median age of 15 patients was 59 years (range 25-71), with 10 males (66.7%). All patients were in advanced stage according to Ann Arbor staging system, with 13 patients in stage IV, and 2 in stage III. 11(73.3%) patients had ≥2 extranodal lesions and 9 (60%) patients had higher LDH level at baseline. 1 patient had TP53 mutation, and 6 patients (40%) had double expressor lymphoma (DEL) (Table 1). The overall best ORR and CR were 100% and 60%, respectively. The CR rate in 6 DEL patients were 50%; Patients with ≥2 extranodal lesions reached a CR of 54.5% (n=11), while 3 out of 4 patients with≤1 extranodal lesions completely responded. The CR rates of patients with Ki-67≥80% vs<80% were 50% vs 62.5%, respectively. Median PFS and OS were not reached yet with a median follow-up of 8 months (range 2-11 months). 2 patients had progressive disease with 1 progressed after C4 and the other 1 after C6. 4 patients with viral hepatitis (3 HBV, 1 HCV) were administered both anti-tumor and antiviral therapy, and their HBV-DNA and HCV-RNA levels continuously declined (till undetectable) along with their tumor load (3 CR ,1 PR). Common treatment-relate adverse events (grade 3/4, all grades) included: leukopenia (80%, 93%), neutropenia (73%, 87%), anemia (27%, 93%), thrombocytopenia (27%, 67%), lymphopenia (20%, 27%), anorexia (13%, 40%), pneumonia (13%,40%), hypertriglyceridemia (7%, 40%), diarrhea (7%, 20%). All AEs were managed with appropriate supportive care and dose adjustments. 8 out of 15 patients had a dose reduction of selinexor to 40mg (initial dose 60mg QW) due to AE, 3 in C2 and the other 5 in C4-C5. All patients were continuously treated after dose reduction, and no treatment-related deaths occurred. Overall, 6 patients completed 6 cycles of selinexor+R-CHOP treatment with sustained remission, and 6 patients were still receiving therapy at time of writing this abstract (4 in C6, 2 in C3). 3 patients ended study, 2 PD and 1 withdrew informed consent after PR at the end of C4 (Figure 1). Conclusion Once weekly 60mg selinexor can be safely combined with R-CHOP in ND high risk (IPI 3-5) GCB subtype DLBCL patients with ORR of 100% and CR of 60%. No viral reactivation was observed in patients with viral hepatitis with simultaneous antiviral therapy.

Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Selinexor for the treatment of patients with relapsed or refractory multiple myeloma

Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis

Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series

Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design

Selinexor in Combination with R-GDP/R-ICE Regimen for Refractory Aggressive Large B-Cell Lymphoma Patients with TP53 Alterations

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease

Selinexor in Combination with Salvage Regimen for Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients with TP53 Alterations